Elicitor peptides for controlling soybean fusarium diseases
A plant-derived peptide-based seed treatment approach to control soil-borne soybean diseases caused by Fusarium graminearum and Fusarium virguliforme. Synthetic variants of soybean elicitor peptides (GmPeps) activate plant defense responses and show direct antifungal activity, offering a potential alternative to traditional fungicides for managing seedling disease and sudden death syndrome.
Overview
Soybean production faces significant yield losses from soil-borne fungal diseases caused by Fusarium graminearum (seedling disease) and Fusarium virguliforme (sudden death syndrome). This research explores the use of synthetic plant elicitor peptides (Peps) as a novel seed treatment to activate the soybean plant's own defense pathways while simultaneously inhibiting fungal growth. The approach leverages eight putative soybean Peps (GmPeps), each 23 amino acids long, that can be applied exogenously to stimulate systemic defense responses without compromising plant growth or yield.
Technical specifications
- Elicitor peptide platform: Eight putative GmPeps identified in soybean, each 23 amino acids in length, designed to activate plant innate immunity
- Dual mechanism of action: Activation of plant defense genes and pathways combined with direct antifungal activity against Fusarium spp.
- In vitro validation results: A variant of GmPepX inhibited Botrytis cinerea growth with MIC values of 1.5–6 μM depending on spore age, and inhibited two-month-old F. graminearum with an MIC of 3 μM
- Application method: Seed treatment at low micromolar concentrations using soybean cultivars Blackhawk and/or Williams 82
- Target pathogens: Fusarium graminearum (soybean seedling disease) and Fusarium virguliforme (sudden death syndrome)
- Future development pathway: Includes testing of chemically synthesized GmPeps for systemic defense activation and generation of transgenic soybean lines overexpressing active GmPeps for enhanced resistance
Technology readiness level
The technology is currently at an early-to-mid stage of development. In vitro antifungal assays have demonstrated that a GmPepX variant inhibits both B. cinerea and F. graminearum growth at micromolar concentrations. Future validation will include testing chemically synthesized GmPeps as seed treatments to assess defense gene activation, potential effects on growth and yield, and efficacy against soil-borne F. graminearum and F. virguliforme using established disease testing protocols. Additional work will involve generating transgenic soybean lines overexpressing active GmPeps to evaluate resistance to these fungal pathogens.
About Danforth Plant Science Center
The Donald Danforth Plant Science Center is a leading independent, nonprofit research institute in St. Louis with a multidisciplinary research community focused on plant science. Corporate engagement is built into the campus through co‑located labs, flexible leased space, and shared core facilities that enable side‑by‑side collaboration with startups and established R&D teams. Its location within a regional agtech innovation district places partners near major corporate hubs, venture networks, and field‑to‑lab testing resources. Research is supported by competitive federal funding from agencies such as the NSF, USDA, and DOE, alongside industry‑sponsored projects and philanthropy. A dedicated technology transfer office provides IP management, licensing, and venture formation support.
delivered to your inbox.